가격과 가치 비교
- Price
- $83.10
- Fair value
- $104.80
- Potential value
- $185.52
- As of
- 2026-09-18
투자 논리가 성립할 수 있는 이유
Restoring retail distribution breadth and consumer volume following supply disruptions drives fiscal 2027 net sales toward consensus estimates of $7,630M, enabling fixed-cost absorption to lift operating margins toward the 18.80% industry benchmark and advancing equity value toward Fair value of $104.80.
관점을 바꿀 요인
Reported fiscal 2027 net sales growth falls below 8.0% YoY over the next 12 months.
Clorox is rated a Buy as retail distribution recovery offers 26.1% upside to our Fair value of $104.80, balanced against elevated debt of $5,520M.4
We rate The Clorox Company a Buy, indicating that the shares offer an attractive entry point for investors seeking operational recovery.
On September 18, 2026, the report was prepared with the stock at $83.10. This price stands 26.1% below our Fair value of $104.80, with long-term potential reaching $185.52 if turnaround execution accelerates.4
The primary risk is that retail shelf-space recovery fails if store brands permanently displace Clorox products. If fiscal 2027 sales growth stalls below 8.0%, operating cash flow will drop, making it difficult to service $5,520M in debt.